ELSA CORREA: Open Payments
NPI 1487620423 · REISTERSTOWN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,810 in 93 payments from 12 companies in 2025. Trend: 2023 $1,374 · 2024 $1,928 · 2025 $1,810
Food & beverage: $1,653Education: $157
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 12 | $356 |
| Alkermes, Inc. | 20 | $332 |
| Neurocrine BioSciences, Inc. | 16 | $247 |
| ABBVIE INC. | 15 | $185 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $147 |
| Axsome Therapeutics, Inc. | 4 | $113 |
| Lundbeck LLC | 5 | $112 |
| Vanda Pharmaceuticals Inc. | 3 | $91 |
| Otsuka America Pharmaceutical, Inc. | 5 | $82 |
| Corium, LLC | 2 | $63 |
Products named: ARISTADA, INGREZZA, VRAYLAR, UZEDY, REXULTI, CAPLYTA, FANAPT, Auvelity.
Industry payments across MD — which companies pay providers there.
